Skip to main content
Search
Search for:
Français
About Us
Mission & Vision
Our Impact
KRESCENT Team
Partners
Contact Us
Awardees
Funding Opportunities
Curriculum
Our Impact
Our Impact
In line with its aim of enhancing kidney research capacity in Canada, the KRESCENT program is focused on the recruitment and training of those who will subsequently assume leadership roles in kidney research. It provides salary support to post-doctoral fellows, new investigators and allied health scholars, as well as career development and mentorship.
Since its inception in 2005, the impact of the KRESCENT program has been significant:
Almost $1 million invested in research in 2018 alone
A high success rate (79%) of obtaining continued grant funding from the CIHR amongst new investigators, with 90% of trainees reporting that KRESCENT has contributed significantly to their success in obtaining CIHR funding
The creation of 72 training positions in 7 provinces
76% of post-doctoral fellows received academic appointments at the Assistant Professor level within 8 months of completing training
Important contributions to the creation of scientific knowledge and development of new methodologies
An increase in the overall impact of kidney research as a percentage of all health research in Canada, outperforming other countries internationally, (comparing 2000 to 2005 and 2009 to 2014 data)
Increased productivity, multi-authored papers, impact and collaborations, (including international collaborations), amongst investigators receiving KRESCENT training and support when compared with non-funded applicants
Areas of research that received new funding from the KRESCENT program in 2018 include the following:
Kidney biology
Organ donation
Chronic Kidney Disease (CKD)
Dialysis
Diabetes
The impact of the KRESCENT program is a testimony to the leadership of the individuals, organizations and companies committed to reducing the burden of kidney disease throughout Canada, and the Kidney Foundation – together with the CSN – have committed to supporting KRESCENT through 2021 and potentially beyond.